Table 1.
Cohort characteristics of patients with cirrhosis in the harmonized Texas Hepatocellular Carcinoma Consortium (THCCC) and the Houston Veterans Administration Cirrhosis Surveillance Cohorts (HVASC) [Derivation Cohort] and the Veterans Health Administration Cirrhosis Cohort [Validation Cohort].
| Characteristics, N % | Derivation Cohort | Validation Cohort |
|---|---|---|
| Age in years, mean (SD) | 60.0 (9.92) | 64.4 (7.65) |
| Gender | ||
| Male | 1729 (68.6) | 20742 (96.3) |
| Female | 791 (31.4) | 808 (3.7) |
| Race/Ethnicity | ||
| Non-Hispanic (NH) white | 1250 (49.6) | 13134 (61.0) |
| NH-Black | 500 (19.8) | 5382 (25.0) |
| Hispanic | 701 (27.8) | 1366 (6.3) |
| Other | 69 (2.7) | 1668 (7.7) |
| Alcohol use | ||
| Never | 775 (30.8) | 8097 (37.6) |
| Current heavy | 173 (6.8) | 4528 (21.0) |
| Other alcohol use (past history or current non-heavy) | 1572 (62.4) | 8925 (41.4) |
| Smoking | ||
| Never | 968 (38.4) | 5167 (24.0) |
| Current | 580 (23.0) | 9165 (42.5) |
| Past | 972 (38.6) | 7218 (33.5) |
| Metabolic traits | ||
| Diabetes | 1094 (43.4) | 12363 (57.4) |
| Body mass index (kg/m2) | 30.9 (6.9) | 30.0 (6.3) |
| Etiology of liver disease | ||
| Active HCV | 479 (19.0) | 1617 (7.5) |
| Cured HCV | 615 (24.4) | 9884 (45.9) |
| Alcohol related liver disease | 419 (19.0) | 6812 (31.6) |
| Nonalcoholic fatty liver disease | 714 (28.3) | 3237 (15.0) |
| Laboratory data, mean (SD) | ||
| Serum bilirubin (mg/dL) | 1.33 (1.5) | 1.02 (1.2) |
| Serum albumin (g/dL) | 3.74 (0.6) | 3.84 (0.6) |
| Alanine aminotransferase (IU/L) | 41.2 (38.6) | 37.5 (43.0) |
| Aspartate aminotransferase (IU/L) | 50.0 (40.9) | 44.1 (70.1) |
| International normalized ratio | 1.22 (0.5) | 1.40 (1.5) |
| Platelet count (106/mL) | 137.3 (70.1) | 158.7 (72.7) |
| Alpha fetoprotein (ng/mL) | 6.83 (14.4) | 10.8 (69.7) |
In total, 1078 (5.0) of patients in the external validation cohort had missing information on race.